CSIMarket Company Name, Ticker, Competitors, else..
 
Tenax Therapeutics Inc   (NASDAQ: TENX)
 
Price: $1.8700 $0.01 0.538%
Day's High: $1.8899999856948853 Week Perf: -5.56 %
Day's Low: $ 1.83 30 Day Perf: 2.19 %
Volume (M): 1,268,121 52 Wk High: $ 19.40
Volume (M$): $ 0 52 Wk Avg: $10.83
Open: $1.84 52 Wk Low: $1.31



 Market Capitalization (Millions $) 95
 Shares Outstanding (Millions) 51
 Employees 16
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -65
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 0

Business Description


Tenax Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of products for the critical care market. The company is focused on addressing the needs of patients suffering from diseases and conditions with significant unmet medical need. Tenax Therapeutics is committed to developing innovative therapies that improve patient outcomes and quality of life. The company's key product candidate is levosimendan, a calcium sensitizer and potassium channel activator, which is being developed for use in treating patients with pulmonary hypertension associated with heart failure and low cardiac output syndrome after cardiac surgery. Tenax Therapeutics aims to become a leader in the critical care market by developing effective and safe therapies that optimize patient care.


   Company Address: 101 Glen Lennox Drive Chapel Hill 27517 NC
   Company Phone Number: 855-2100   Stock Exchange / Ticker: NASDAQ TENX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
INVA   -1.73%    
PFE   -2.48%    
TEVA        6.46% 
UTHR        2.99% 
VRTX   -5.03%    
VTRS   -1.24%    
• View Complete Report
   



Clinical Study

Tenax Therapeutics Expands Phase 3 LEVEL Program Amid Financial Challenges

Published Sun, Mar 9 2025 10:53 AM UTC

Tenax Therapeutics, a biopharmaceutical company focused on developing innovative therapies for pulmonary hypertension and heart failure, has announced the expansion of its Phase 3 LEVEL program. This initiative includes the progression of two TNX-103 (Oral Levosimendan) registrational studies for treating pulmonary hypertension associated with heart failure with preserved ej...
Shares

Tenax Therapeutics $25 Million Private Placement: Catalyzing Cardiopulmonary Innovation and Shareholder Value,

Published Wed, Mar 5 2025 1:47 PM UTC

Tenax Therapeutics Secures $25 Million in Private Placement: A Boost for Cardiopulmonary InnovationIn a strategic financial maneuver, Tenax Therapeutics, Inc. (Nasdaq: TENX) has announced the successful agreement of a securities purchase transaction, culminating in a substantial private placement financing with RTW Investments. Expected to inject approximately $25 million in...
Management Announcement

Tenax Therapeutics Expands Global Rights to Revolutionary Treatment for Pulmonary Hypertension

Published Tue, Feb 20 2024 1:30 PM UTC



In a major breakthrough for the field of cardiovascular and pulmonary medicine, Tenax Therapeutics, a Phase 3, development-stage pharmaceutical company, has announced a significant expansion of its global development, commercial, and intellectual property rights to a life-changing treatment known as levosimendan. This development holds immense promise for patients ...
Clinical Study

Tenax Therapeutics Launches Groundbreaking Phase 3 Study Evaluating Novel Treatment for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Published Thu, Feb 8 2024 1:01 AM UTC

In a major stride towards combatting the debilitating heart condition known as Heart Failure with Preserved Ejection Fraction (HFpEF), Tenax Therapeutics has successfully enrolled the first patient in their groundbreaking Phase 3 study. The clinical trial, named LEVEL, aims to evaluate the effectiveness of TNX-103, an oral medication based on levosimendan, in treating the as...
Shares

Tenax Therapeutics Executes Reverse Stock Split to Foster Cardiovascular Market Expansion

Published Fri, Dec 29 2023 1:30 PM UTC



Chapel Hill-based specialty pharmaceutical company Tenax Therapeutics, Inc. (Nasdaq: TENX) has recently announced a significant strategic move that will reshape its capital structure and potentially open new avenues for growth. The company is set to execute a reverse stock split at a ratio of 1-for-80, aimed at strengthening its position in addressing the unmet med...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.84
PEG (TTM) -

Financial Strength Current
Quick Ratio 14.62
Working Capital Ratio 15.07
Leverage Ratio (MRQ) 0.07
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.5 $
Revenues (TTM) -
Cash Flow (TTM) 0.26 $
Cash 2.32 $
Book Value 2.23 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -4,053,938
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.